- Home
- ASTC vs APRE Comparison
ASTC vs APRE Comparison
Compare ASTC & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASTC | APRE |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 6.9M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ASTC | APRE |
|---|---|---|
| Price | $3.86 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 116.9K | 71.8K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,312,000.00 | $488,239.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.06 | N/A |
| 52 Week Low | $2.47 | $0.90 |
| 52 Week High | $8.15 | $5.00 |
Technical Indicators
Market Signals| Indicator | ASTC | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 56.79 | 30.33 |
| Support Level | $3.13 | $0.90 |
| Resistance Level | $3.43 | $1.14 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 63.03 | 6.44 |
Price Performance
Historical ComparisonAbout ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.